GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Global Biotech Inc (ROCO:6808) » Definitions » EV-to-EBIT

3D Global Biotech (ROCO:6808) EV-to-EBIT : -28.50 (As of May. 16, 2024)


View and export this data going back to 2020. Start your Free Trial

What is 3D Global Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, 3D Global Biotech's Enterprise Value is NT$1,674.26 Mil. 3D Global Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-58.74 Mil. Therefore, 3D Global Biotech's EV-to-EBIT for today is -28.50.

The historical rank and industry rank for 3D Global Biotech's EV-to-EBIT or its related term are showing as below:

ROCO:6808' s EV-to-EBIT Range Over the Past 10 Years
Min: -66.67   Med: -23.63   Max: -9.67
Current: -28.49

During the past 7 years, the highest EV-to-EBIT of 3D Global Biotech was -9.67. The lowest was -66.67. And the median was -23.63.

ROCO:6808's EV-to-EBIT is ranked worse than
100% of 429 companies
in the Biotechnology industry
Industry Median: 9.84 vs ROCO:6808: -28.49

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. 3D Global Biotech's Enterprise Value for the quarter that ended in Dec. 2023 was NT$949.30 Mil. 3D Global Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-58.74 Mil. 3D Global Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -6.19%.


3D Global Biotech EV-to-EBIT Historical Data

The historical data trend for 3D Global Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Global Biotech EV-to-EBIT Chart

3D Global Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - -48.93 -31.80 -15.81 -16.16

3D Global Biotech Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.80 - -15.81 - -16.16

Competitive Comparison of 3D Global Biotech's EV-to-EBIT

For the Biotechnology subindustry, 3D Global Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3D Global Biotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Global Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 3D Global Biotech's EV-to-EBIT falls into.



3D Global Biotech EV-to-EBIT Calculation

3D Global Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1674.255/-58.739
=-28.50

3D Global Biotech's current Enterprise Value is NT$1,674.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3D Global Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-58.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3D Global Biotech  (ROCO:6808) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

3D Global Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-58.739/949.29805
=-6.19 %

3D Global Biotech's Enterprise Value for the quarter that ended in Dec. 2023 was NT$949.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3D Global Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-58.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3D Global Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of 3D Global Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


3D Global Biotech (ROCO:6808) Business Description

Traded in Other Exchanges
N/A
Address
No.99, Sec. 1, Xintai 5th Rd, 21st Floor -3, Xizhi District, New Taipei, TWN, 221
3D Global Biotech Inc is engaged in developing reconstruction of human tissues and organs and manufactures customized and personalized high-level medical devices.

3D Global Biotech (ROCO:6808) Headlines

No Headlines